^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    bortezomib (Proteasome inhibitor) +
    dexamethasone (GCR agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

    Published date:
    10/29/2020
    Excerpt:
    In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma…median progression-free survival according to independent review committee was 22·4 months (95% CI 15·3–not estimable) with venetoclax...The primary endpoint was met with a significant improvement in independent review committee-assessed progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone.
    DOI:
    10.1016/S1470-2045(20)30525-8
    Trial ID:
    BELLINI